Antidepressant-Induced Sexual Dysfunction and Associated Treatments
Summary
Antidepressant-induced sexual dysfunction encompasses a spectrum of disturbances—loss of libido, delayed orgasm or anorgasmia, erectile dysfunction and reduced genital sensitivity—that affect up to two thirds of individuals treated with modern antidepressant agents. These adverse effects arise principally from serotonergic modulation of central and peripheral circuits, with additional contributions from noradrenergic, dopaminergic and hormonal pathways. Although depressive symptom remission often restores sexual function, dysfunction may persist during treatment or emerge after discontinuation, as in post-SSRI sexual dysfunction (PSSD). Such sequelae substantially impair quality of life, intimate relationships and medication adherence, thereby jeopardising long-term outcomes. Management strategies range from prevention—selecting agents with lower sexual side-effect burdens or using brief “drug holidays”—to pharmacological interventions, including dose reduction, adjunctive bupropion or phosphodiesterase-5 inhibitors, and non-pharmacological approaches such as psychoeducation and brief behavioural therapy. Recent advances have elucidated genetic predispositions, refined receptor-targeting agents and explored novel delivery systems, underscoring the need for personalised therapeutic regimens that balance mood improvement with sexual well-being.
Research from Nature Portfolio
Emerging evidence highlights the role of individual genetic liability in shaping susceptibility to sexual side effects across antidepressant classes. Large-scale analyses integrating polygenic risk scores for depression severity, body mass index, insomnia and headache reveal that shared genetic factors underlie diverse adverse reactions, including sexual dysfunction. Individuals with higher depression polygenic risk are more prone to low libido and delayed orgasm, while BMI-related genetic profiles predict weight gain and associated sexual concerns. These findings point to a common aetiological framework in which genomic markers may inform risk stratification and guide prophylactic strategies, paving the way for tailored antidepressant selection and early supportive interventions.
Antidepressant-Induced Sexual Dysfunction and Associated Treatments publication trend
The graph below shows the total number of articles in antidepressant-induced sexual dysfunction and associated treatments across all publications each year (not limited to Nature Index journals).
Technical terms
Selective serotonin reuptake inhibitors (SSRIs): A class of antidepressants that increase synaptic serotonin by blocking its reuptake transporter.
Serotonin-norepinephrine reuptake inhibitors (SNRIs): Antidepressants that inhibit the reuptake of both serotonin and norepinephrine, affecting mood and pain pathways.
Treatment-emergent sexual dysfunction (TESD): Sexual side effects that appear or worsen following initiation of antidepressant therapy.
Post-SSRI sexual dysfunction (PSSD): A condition characterised by enduring sexual dysfunction persisting after discontinuation of SSRI treatment.
Phosphodiesterase type 5 inhibitors (PDE5-I): Medications that enhance erectile function by increasing cyclic GMP levels in penile tissue.
References
- Reasons for Discontinuation or Change of Selective Serotonin Reuptake Inhibitors in Online Drug Reviews. JAMA Network Open (2023).
- The pathophysiology of Post SSRI Sexual Dysfunction – Lessons from a case study. Biomedicine & Pharmacotherapy (2023).
- What is the impact of antidepressant side effects on medication adherence among adult patients diagnosed with depressive disorder: A systematic review. Journal of Psychopharmacology (2024).
- Management Strategies for Antidepressant-Related Sexual Dysfunction: A Clinical Approach. Journal of Clinical Medicine (2019).
- Understanding genetic risk factors for common side effects of antidepressant medications. Communications Medicine (2021).
- Niosomal Bupropion: Exploring Therapeutic Frontiers through Behavioral Profiling. Pharmaceuticals (2024).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.